Abstract
Antibiotics that interfere with translation, when combined, interact in diverse and difficult-to-predict ways. Here, we explain these interactions by "translation bottlenecks": points in the translation cycle where antibiotics block ribosomal progression. To elucidate the underlying mechanisms of drug interactions between translation inhibitors, we generate translation bottlenecks genetically using inducible control of translation factors that regulate well-defined translation cycle steps. These perturbations accurately mimic antibiotic action and drug interactions, supporting that the interplay of different translation bottlenecks causes these interactions. We further show that growth laws, combined with drug uptake and binding kinetics, enable the direct prediction of a large fraction of observed interactions, yet fail to predict suppression. However, varying two translation bottlenecks simultaneously supports that dense traffic of ribosomes and competition for translation factors account for the previously unexplained suppression. These results highlight the importance of "continuous epistasis" in bacterial physiology.
The Challenge of Predicting Antibiotic Interactions
When combining two antibiotics, the outcome is rarely a simple sum of their individual effects. Interactions can be synergistic (enhanced effect), antagonistic (reduced effect), or suppressive—where the addition of a second drug counterintuitively improves bacterial growth. Predicting these interactions is a long-standing goal in clinical pharmacology and evolutionary biology. While statistical models like Loewe additivity help classify these outcomes, a mechanistic understanding of why specific drugs interact in certain ways has remained elusive, particularly for those targeting the bacterial ribosome.
Mapping Translation Bottlenecks
To decode these interactions, researchers treated the ribosome's journey along mRNA as a series of "bottlenecks." They focused on eight representative antibiotics that target different stages of the translation cycle: initiation, elongation, translocation, and recycling.
The study employed a multi-pronged approach:
- High-Resolution Growth Assays: Measuring E. coli growth across 28 pairwise drug combinations using bioluminescence.
- Genetic Mimicry: Engineering synthetic E. coli strains where essential translation factors (e.g., infB for initiation or fusA for translocation) were under inducible control. This allowed the creation of "genetic bottlenecks" that precisely isolated the physiological effects of specific drug actions.
- Biophysical Modeling: Combining bacterial "growth laws"—the quantitative link between ribosome abundance and growth rate—with drug-binding kinetics.
- Traffic Flow Theory (TASEP): Applying the Totally Asymmetric Simple Exclusion Process (TASEP), a mathematical framework for modeling traffic flow, to ribosomes moving along an mRNA strand.
Key Insights: Ribosome Traffic Jams
The researchers discovered that antibiotics act as specific roadblocks. While a standard biophysical model based on growth laws explained approximately 57% of interactions (mostly additive or synergistic), it failed to account for suppression.
The breakthrough came from viewing ribosomes as cars on a highway. If a drug like Fusidic acid (FUS) slows down translocation, ribosomes pile up in a "traffic jam," sequestering molecular resources and stalling growth. However, adding a second drug like Kasugamycin (KSG), which inhibits initiation (the "on-ramp"), reduces the number of ribosomes entering the mRNA. This clears the congestion, allowing the remaining ribosomes to move more efficiently and, remarkably, increasing the overall growth rate.
Results and Implications
By remapping antibiotic effects onto genetic bottlenecks, the authors successfully predicted 71% of observed drug interactions. This included the discovery of a previously unreported synergy between capreomycin (CRY) and chloramphenicol (CHL).
The study provides the first clear physiological explanation for suppression: initiation inhibitors can alleviate the "traffic jams" caused by translocation inhibitors. This concept of "continuous epistasis"—where titrating gene expression reveals the underlying topology of cellular physiology—offers a powerful framework for understanding complex biological systems.
Limitations and Future Directions
While the bottleneck model is highly effective, it does not capture all interactions (missing 29%). These discrepancies likely stem from "off-target" effects, such as interference with drug uptake or membrane stress, and the inherent complexity of the ribosome as a massive molecular machine. Future work may extend this "bottleneck" approach to other multi-step metabolic pathways, potentially aiding the prediction of drug interactions in cancer or metabolic diseases.
Reference: Kavčič, B., Tkačik, G. & Bollenbach, T. Mechanisms of drug interactions between translation-inhibiting antibiotics. Nat Commun 11, 4013 (2020). https://doi.org/10.1038/s41467-020-17734-z
Summary updated